Stanford Actionable Mutation Panel for Solid Tumors (STAMP)

The STAMP assay detects potentially clinically actionable mutations, as well as additional genes that are frequently mutated in cancers. The Stanford Actionable Mutation Panel for Solid Tumors (STAMPT) is a targeted next generation sequencing method that uses target enrichment to capture genomic regions of interest. The targeted sequencing approach and integrated bioinformatics workflow is optimized for ultra-deep sequencing of formalin fixed tumor biopsy tissue specimens. The workflow includes acoustic shearing of isolated genomic DNA, followed by efficient preparation of sequencing libraries and a target enrichment approach to capture genomic regions of interest for sequencing. The enrichment is done using custom designed libraries of capture oligonucleotides that target a specific set of genomic regions. This panel targets clinical actionable genes, either in part or fully, with the genes selected on the basis of their known impact as actionable targets of existing and emerging anti-cancer therapies, their prognostic features, and/or their mutation recurrence frequency across patients with known cancer types. Pooled libraries are sequenced on an Illumina sequencing instrument. This test is at minimum limit of detection at 5%. Genomic positions are given in reference to the GRCh37 (hg19) assembly of the human genome. Please consult the gene list under results tab for the latest version of STAMP.